Please login to the form below
Horizant
This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.
US shortage of GSK’s restless legs syndrome treatment Horizant
FDA blames contract manufacturer delays. Delays at GlaxoSmithKline's (GSK) contract manufacturer have caused a shortage in the US of restless legs syndrome treatment Horizant, according to the FDA. ... Then in November 2012, GSK and XenoPort agreed to
Latest news
-
GSK sales fall for first quarter of 2011
Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).
-
GSK Restless Legs Syndrome drug approved
GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs Syndrome. ... Horizant's approval for the condition was based on two 12-week clinical
-
FDA rejects GSK and Xenoport's Horizant
GSK and XenoPort, have received a Complete Response letter from the US FDA relating to Horizant (gabapentin enacarbil). ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch May 2016
399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Global Business Development Director – Health Education
-
excellent commission
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
-
Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Account Director, Medical Education
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- AZ’s Sean Bohen to exit after business overhaul; report
- FDA moves into crisis mode as shutdown drags on
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
bmore group
OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....
Latest intelligence
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Quick links
Infographics
